Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells

Cellular Oncology

Volumn 39, Issue 1, 2016, Pages 79-87

  Jang, Boonsil ^a   Shin, Ji Ae ^a   Kim, Yong Soo ^a   Kim, Ji Young ^b   Yi, Ho Keun ^a   Park, Il Song ^a   Cho, Nam Pyo ^a   Cho, Sung Dae ^a  

^a Chonbuk National University   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

Apoptosis; ERK; Oral cancer; Saha

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTINEOPLASTIC AGENT; CASPASE 3; HISTONE H2A; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OKADAIC ACID; SELUMETINIB; VORINOSTAT; CASPASE; HISTONE; HYDROXAMIC ACID; PROTEIN KINASE INHIBITOR;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CARCINOGENESIS; CELL COUNT; CELL VIABILITY; COLONY FORMATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; ORAL CANCER CELL LINE; PERIODONTAL LIGAMENT; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION; ACETYLATION; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; METABOLISM; MOUTH TUMOR; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; TUMOR STEM CELL ASSAY;

ACETYLATION; ANIMALS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; MALE; MICE; MOUTH NEOPLASMS; OKADAIC ACID; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955411158     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-015-0255-3     Document Type: Article

References (34)

1. C. Florean, M. Schnekenburger, C. Grandjenette, M. Dicato, M. Diederich, Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics 3, 581–609 (2011). doi:10.2217/epi.11.73
2. P. Zhu, E. Martin, J. Mengwasser, P. Schlag, K.P. Janssen, M. Gottlicher, Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5, 455–463 (2004)
3. Z. Zhang, H. Yamashita, T. Toyama, H. Sugiura, Y. Ando, K. Mita, M. Hamaguchi, Y. Hara, S. Kobayashi, H. Iwase, Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res. Treat. 94, 11–16 (2005). doi:10.1007/s10549-005-6001-1
4. E. Yiannakopoulou, Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents–implications for cancer treatment and chemoprevention. Cell. Oncol. 37, 167–178 (2014). doi:10.1007/s13402-014-0175-7
5. B.H. Huang, M. Laban, C.H. Leung, L. Lee, C.K. Lee, M. Salto-Tellez, G.C. Raju, S.C. Hooi, Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 12, 395–404 (2005). doi:10.1038/sj.cdd.4401567
6. K.B. Glaser, J. Li, M.J. Staver, R.Q. Wei, D.H. Albert, S.K. Davidsen, Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Comm. 310, 529–536 (2003)
7. P.A. Marks, The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin. Investig. Drugs 19, 1049–1066 (2010). doi:10.1517/13543784.2010.510514
8. H. Yamamoto, J. Fujimoto, E. Okamoto, J. Furuyama, T. Tamaoki, T. Hashimoto-Tamaoki, Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo. Int. J. Cancer 76, 897–902 (1998)
9. S.T. Nawrocki, J.S. Carew, L. Douglas, J.L. Cleveland, R. Humphreys, J.A. Houghton, Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res. 67, 6987–6994 (2007). doi:10.1158/0008-5472.CAN-07-0812
10. D. Siegel, M. Hussein, C. Belani, F. Robert, E. Galanis, V.M. Richon, J. Garcia-Vargas, C. Sanz-Rodriguez, S. Rizvi, Vorinostat in solid and hematologic malignancies. J. Hematol. Oncol. 2, 31 (2009). doi:10.1186/1756-8722-2-31
11. D. Kurundkar, R.K. Srivastava, S.C. Chaudhary, M.E. Ballestas, L. Kopelovich, C.A. Elmets, M. Athar, Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Toxicol. Appl. Pharmacol. 266, 233–244 (2013). doi:10.1016/j.taap.2012.11.002
12. G. Silva, B.A. Cardoso, H. Belo, A.M. Almeida, Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms. PLoS One 8, e53766 (2013). doi:10.1371/journal.pone.0053766
13. M.N. Siddiquey, H. Nakagawa, S. Iwata, T. Kanazawa, M. Suzuki, K. Imadome, S. Fujiwara, F. Goshima, T. Murata, H. Kimura, Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma. Cancer Sci. 105, 713–722 (2014). doi:10.1111/cas.12418
14. S. Chen, Y. Zhao, W.F. Gou, S. Zhao, Y. Takano, H.C. Zheng, The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells. PLoS One 8, e79781 (2013). doi:10.1371/journal.pone.0079781
15. C. Cortes, S.C. Kozma, A. Tauler, S. Ambrosio, MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells. Cell. Oncol. 38, 341–352 (2015). doi:10.1007/s13402-015-0233-9
16. L. Ellis, R. Pili, Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals 3, 2411–2469 (2010). doi:10.3390/ph3082441
17. D. Yin, J.M. Ong, J. Hu, J.C. Desmond, N. Kawamata, B.M. Konda, K.L. Black, H.P. Koeffler, Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 13, 1045–1052 (2007). doi:10.1158/1078-0432.CCR-06-1261
18. P.N. Munster, T. Troso-Sandoval, N. Rosen, R. Rifkind, P.A. Marks, V.M. Richon, The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 61, 8492–8497 (2001)
19. J.A. Shin, G. Han, H.J. Kim, H.M. Kim, S.D. Cho, Chemopreventive and chemotherapeutic effect of a novel histone deacetylase inhibitor, by specificity protein 1 in MDA-MB-231 human breast cancer cells. Eur. J. Cancer Prev. 23, 277–285 (2014). doi:10.1097/CEJ.0000000000000041
20. A. Hrzenjak, F. Moinfar, M.L. Kremser, B. Strohmeier, E. Petru, K. Zatloukal, H. Denk, Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol. Cancer 9, 49 (2010). doi:10.1186/1476-4598-9-49
21. X. Sun, Z.S. Hasanali, A. Chen, D. Zhang, X. Liu, H.G. Wang, D.J. Feith, T.P. Loughran Jr., K. Xu, Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia. Br. J. Haematol. 168, 371–383 (2015). doi:10.1111/bjh.13143
22. Y. Wang, W.Z. Kong, L.H. Xing, X. Yang, Effects and mechanism of suberoylanilide hydroxamic acid on the proliferation and apoptosis of human hepatoma cell line bel-7402. J. BUON 19, 698–704 (2014)
23. T.G. Lee, E.H. Jeong, S.Y. Kim, H.R. Kim and C.H. Kim, The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer. Int. J. Cancer (2014) doi:10.1002/ijc.29320
24. R.T. Allen, W.J. Hunter 3rd, D.K. Agrawal, Morphological and biochemical characterization and analysis of apoptosis. J. Pharmacol. Toxicol. Methods 37, 215–228 (1997)
25. Z. Jin, W.S. El-Deiry, Overview of cell death signaling pathways. Cancer Biol. Ther. 4, 139–163 (2005)
26. M. Suzuki, M. Endo, F. Shinohara, S. Echigo, H. Rikiishi, Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. Cancer Chemother. Pharmacol. 64, 1115–1122 (2009). doi:10.1007/s00280-009-0969-x
27. Y.H. Kim, D.H. Lee, J.H. Jeong, Z.S. Guo, Y.J. Lee, Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem. Pharmacol. 75, 1946–1958 (2008). doi:10.1016/j.bcp.2008.02.016
28. C.A. Hollmann, T. Owens, J. Nalbantoglu, T.J. Hudson, R. Sladek, Constitutive activation of extracellular signal-regulated kinase predisposes diffuse large B-cell lymphoma cell lines to CD40-mediated cell death. Cancer Res. 66, 3550–3557 (2006). doi:10.1158/0008-5472.CAN-05-2498
29. Y.J. Lee, H.N. Cho, J.W. Soh, G.J. Jhon, C.K. Cho, H.Y. Chung, S. Bae, S.J. Lee, Y.S. Lee, Oxidative stress-induced apoptosis is mediated by ERK1/2 phosphorylation. Exp. Cell Res. 291, 251–266 (2003)
30. F. Chang, L.S. Steelman, J.T. Lee, J.G. Shelton, P.M. Navolanic, W.L. Blalock, R.A. Franklin, J.A. McCubrey, Leukemia 17, 1263–1293 (2003). doi:10.1038/sj.leu.2402945
31. J.T. Lee Jr., J.A. McCubrey, Signal transduction mediated by the ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 16, 486–507 (2002). doi:10.1038/sj.leu.2402460
32. N.P. Judd, A.E. Winkler, O. Murillo-Sauca, J.J. Brotman, J.H. Law, J.S. Lewis Jr., G.P. Dunn, J.D. Bui, J.B. Sunwoo, R. Uppaluri, ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 72, 365–374 (2012). doi:10.1158/0008-5472.CAN-11-1831
33. Y. Wang, S.Y. Wang, C.M. Hou, Y.J. Xu, Z.Y. Du and X.D. Yu, J. Histone deacetylase inhibitor SAHA induces inactivation of MAPK signaling and apoptosis in HL-60 cells. J. Exp. Hematol./Chin. Ass. Pathophysiol. 15, 267–271 (2007)
34. M.J. Nunes, M. Moutinho, I. Milagre, M.J. Gama and E. Rodrigues, J. Okadaic acid inhibits the trichostatin A-mediated increase of human CYP46A1 neuronal expression in a ERK1/2-Sp3-dependent pathway. Lipid Res. 53, 1910–1919 (2012) doi:10.1194/jlr.M027680